These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9225755)

  • 1. 3-Nitropropionic acid neurotoxicity: visualization by silver staining and implications for use as an animal model of Huntington's disease.
    Miller PJ; Zaborszky L
    Exp Neurol; 1997 Jul; 146(1):212-29. PubMed ID: 9225755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia.
    Page KJ; Besret L; Jain M; Monaghan EM; Dunnett SB; Everitt BJ
    Exp Brain Res; 2000 Jan; 130(2):142-50. PubMed ID: 10672467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid.
    Guyot MC; Hantraye P; Dolan R; Palfi S; Maziére M; Brouillet E
    Neuroscience; 1997 Jul; 79(1):45-56. PubMed ID: 9178864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington's disease.
    Chakraborty J; Nthenge-Ngumbau DN; Rajamma U; Mohanakumar KP
    Behav Brain Res; 2014 May; 264():91-104. PubMed ID: 24509309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease.
    Roitberg BZ; Emborg ME; Sramek JG; Palfi S; Kordower JH
    Neurosurgery; 2002 Jan; 50(1):137-45; discussion 145-6. PubMed ID: 11844244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum.
    Vis JC; Verbeek MM; De Waal RM; Ten Donkelaar HJ; Kremer HP
    Neuropathol Appl Neurobiol; 1999 Dec; 25(6):513-21. PubMed ID: 10632901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid.
    Nakao N; Brundin P
    Neuroscience; 1997 Feb; 76(3):749-61. PubMed ID: 9135048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies.
    Ouary S; Bizat N; Altairac S; Ménétrat H; Mittoux V; Condé F; Hantraye P; Brouillet E
    Neuroscience; 2000; 97(3):521-30. PubMed ID: 10828534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity.
    Klivenyi P; Starkov AA; Calingasan NY; Gardian G; Browne SE; Yang L; Bubber P; Gibson GE; Patel MS; Beal MF
    J Neurochem; 2004 Mar; 88(6):1352-60. PubMed ID: 15009635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.
    Shear DA; Dong J; Gundy CD; Haik-Creguer KL; Dunbar GL
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1217-40. PubMed ID: 9829299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic, but not intraparenchymal, administration of 3-nitropropionic acid mimics the neuropathology of Huntington's disease: a speculative explanation.
    Borlongan CV; Nishino H; Sanberg PR
    Neurosci Res; 1997 Jul; 28(3):185-9. PubMed ID: 9237266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial toxin 3-nitropropionic acid induces cardiac and neurotoxicity differentially in mice.
    Gabrielson KL; Hogue BA; Bohr VA; Cardounel AJ; Nakajima W; Kofler J; Zweier JL; Rodriguez ER; Martin LJ; de Souza-Pinto NC; Bressler J
    Am J Pathol; 2001 Oct; 159(4):1507-20. PubMed ID: 11583977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
    Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module.
    Garcia M; Vanhoutte P; Pages C; Besson MJ; Brouillet E; Caboche J
    J Neurosci; 2002 Mar; 22(6):2174-84. PubMed ID: 11896157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease.
    Sun Z; Xie J; Reiner A
    Exp Neurol; 2002 Jul; 176(1):55-65. PubMed ID: 12093082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease.
    Gao Y; Chu SF; Li JP; Zhang Z; Yan JQ; Wen ZL; Xia CY; Mou Z; Wang ZZ; He WB; Guo XF; Wei GN; Chen NH
    Acta Pharmacol Sin; 2015 Mar; 36(3):311-22. PubMed ID: 25640478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats.
    Borlongan CV; Koutouzis TK; Randall TS; Freeman TB; Cahill DW; Sanberg PR
    Brain Res Bull; 1995; 36(6):549-56. PubMed ID: 7538873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lycopene modulates nitric oxide pathways against 3-nitropropionic acid-induced neurotoxicity.
    Kumar P; Kalonia H; Kumar A
    Life Sci; 2009 Nov; 85(19-20):711-8. PubMed ID: 19822156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms.
    Kumar P; Padi SS; Naidu PS; Kumar A
    Behav Pharmacol; 2006 Sep; 17(5-6):485-92. PubMed ID: 16940769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization.
    Ferrante RJ; Kowall NW; Cipolloni PB; Storey E; Beal MF
    Exp Neurol; 1993 Jan; 119(1):46-71. PubMed ID: 8432351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.